What do our competitors see as the future of breast and gynaecological cancers, and where do we fit in?

Our client, a global biopharmaceutical company with a deep legacy in breast cancer, faces increasingly aggressive and innovative competition to their legacy and future in the OBGyn space.

We holistically reviewed the franchise-level strategies of key competitors, including pipelines, partnering, operations and communications, to establish their individual visions for the future of the space in the short/mid/long term, and the level of threat to our client.